

ABBREVIATIONS

ADMET Absorption, distribution, metabolism, elimination, toxicity
AE Adverse event
AIDS Acquired immunodeficiency syndrome
ANC Antenatal care
API Active pharmaceutical ingredient
ART Antiretroviral therapy
ARV Antiretroviral
ATLAS Antiretroviral Therapy as Long-Acting Suppression
B or BIC Bictegravir
bNAb Broadly neutralizing antibody
CAB Cabotegravir
CADO Conference on Antiretroviral Drug Optimization
Calibr California Institute for Biomedical Research
cART Combination antiretroviral therapy
CDMO Contract Development and Manufacture Company
CELT Centre of Excellence in Long-acting Therapeutics
cGLP Current good laboratory practices
cGMP Current good manufacturing practices
CHAI Clinton Health Action Initiative
CMC Chemistry, Manufacturing and Controls
COGs Cost of goods
DAIDS Division of AIDS
DcNP Drug Combination Nanoparticles
DDI drug-drug interaction
DHA Docosahexaenoic acid
DMPK Drug metabolism and pharmacokinetics
DOR Doravine
DSMB Data and Safety Monitoring Board
DTG Dolutegravir
EC50 Effective concentration 50%
eDMC external Data Management Committee
EMA European Medicines Agency
ER Extended Release
ETR Etravirine
ETV Entecavir
FDA Food and Drug Administration

FDF Final dosage form
F or FTC Emtricitabine
GLAD Global Long-Acting Drugs project
HBV Hepatitis B virus
HCV Hepatitis C virus
HIV Human immunodeficiency virus
HPTN HIV Prevention Trials Network
IC50 Inhibitory concentration 50%
IC90 Inhibitory concentration 90%
ID Intradermal
IM Intramuscular
IMPAACT International Maternal, Pediatric, Adolescent AIDS Clinical Trials
IND Investigational New Drug
INH Isoniazid
INSTI Integrase strand transfer inhibitor
IRB Institutional review board
ISL Islatravir
ISR Injection site reaction
IV Intravenous
JHU Johns Hopkins University
LA Long-acting
LAI Long-acting injectable
LaPaL Long-acting technologies Patents and Licences database
LARC Long-acting reversible contraception
LEAP Long-acting Extended-release Antiretroviral research resource Program
LEN Lenacapavir
LMIC Low-middle income country
LPV Lopinavir
MALDI Matrix-Assisted Laser Desorption Ionization
MAP microneedle array patch
MBPK Mechanism-based pharmacokinetic
MN microneedle
MOCHA More Options for Children and Adolescents
MPP Medicines Patent Pool
MTCT Maternal to Child Transmission
NARTI Nucleoside analog reverse transcriptase inhibitor
NHP Non-human primate
NRTTI Nucleoside reverse transcriptase translocation inhibitor

NTAF Nanoformulated TAF
OBR Optimized background regimen
OLI Oral lead in
PADO Paediatric Antiretroviral Drug Optimization
PAIC90 Protein-adjusted inhibitory concentration 90%
PBMC Peripheral blood mononuclear cell
PBPK Physiological-based pharmacokinetic
PD Pharmacodynamic
PK Pharmacokinetic
PLGA Polylactic-co-glycolic acid
PLWH Person living with HIV
PMTCT Prevention of maternal to child transmission
POC Point of care
PPPY per person per year
PrEP Pre-exposure prophylaxis
R&D Research and development
RLS Resource limited setting
RPV rilpivirine
RTV rosinavir
SAE serious adverse event
SC subcutaneous
SD subdermal
SSA sub-Saharan Africa
TAF Tenofovir alafenamide
TAG Treatment Action Group
TB Tuberculosis
TDF Tenofovir disoproxil fumarate
TFV Tenofovir
TFV-DP Tenofovir diphosphate
TFV-MP Tenofovir monophosphate
TK Toxicokinetic
TLC Total lymphocyte count
TLC-ART Targeted Long-acting Combinational ARV Therapeutic
TLD Tenofovir, lamivudine, dolutegravir
TNL Tandem Nano Ltd
UNMC University of Nebraska Medical Center
VL Viral load
WHO World Health Organization